Home

The Translational Research Cancer Centers Consortium (TRCCC) mission is to gain a greater understanding of the interactions between the immune system and cancer in the setting of biologic therapy of cancer.

TRCCC Event News & Events

2014 TRCCC Meeting Keynote Speakers & Registration Deadline Announced
The speaker line-up for the 2014 TRCC Annual Meeting includes keynote presentations from Suzanne Ostrand-Rosenberg, Ph.D., Professor, Robert and Jane Meyerhoff Chair of Biochemistry, University of Maryland Baltimore Campus with present Inflammation, Immune Supression and Cancer: It's the RAGE. Mac Cheever, M.D., Director, Solid Tumor Research, Fred Hutchinson Cancer Research Center, and Director, Cancer Immunotherapy Trials Network will present The Cancer Immunotherapy Network - Priorities, Trials and Goals. The meeting agenda is still being finalized at this time. Once it is confirmed, you can visit this page for the entire schedule of speakers and events.

• Meeting Registration Deadline: January 15, 2014
• Abstract Submission Deadline: January 28, 2014

TRCCC Member News

Roswell Park's Dr. Elizabeth Repasky Speaks to the New York Times about Recent Cancer Treatment Cleared By F.D.A
(December 3, 2013)
When federal regulators permitted the sale of an unproved device that uses intense heat to combat cancer, they did so for a compelling reason, to give hope to some women desperately ill with cervical cancer. However, Dr. Elizabeth Repasky, a hyperthermia expert at the Roswell Park Cancer Institute in Buffalo, said that she worried that the F.D.A.’s decision to approve the BSD-2000 without better data collection could set back the technology rather than advance it. Read More.

Roswell Park Cancer Institute, University of Pittsburgh Cancer Institute Awarded $11 Million SPORE Grant
(October 7, 2013)
With more than $11 million in funding from the National Cancer Institute, Roswell Park Cancer Institute in collaboration with University of Pittsburgh Cancer Institute, will embark on an aggressive, multi-pronged search for ways to prevent and cure it. Distributed over five years, the funds will come through a Specialized Program of Research Excellence (SPORE) grant. The research team, led by Kunle Odunsi, MD, PhD, Principal Investigator of the RPCI/UPCI Ovarian Cancer SPORE grant, will study novel immunotherapy approaches for the treatment of and risk assessment for ovarian cancer. The research itself will encompass four projects: three clinical trials evaluating newly developed immunotherapies and one epidemiological study looking for ways to reduce risk in women at high risk of developing ovarian cancer. For more information, click here.


Founding Director of the University of Pittsburgh Cancer Institute Passes Away
(June 5, 2013)
Ronald Herberman, who died Sunday at age 72, was probably more responsible than anyone for making UPCI what it is today -- a center whose 338 faculty members treat nearly 75,000 cancer patients a year, bringing in more than $155 million in research grants and conducting 250 separate clinical trials. Dr. Herberman came to Pittsburgh in 1985 from the National Cancer Institute in Bethesda, Md., where he had led ground-breaking research with natural killer cells that help a patient's immune system fight cancer. Read More.

To pay tribute to Dr. Ronald Herberman, his family requests that donations be made in his name to the Leukemia & Lymphoma Society. Click here to make a donation.

TRCCC Committee Member and Penn Researcher Wins Philadelphia Award
(June 01, 2013)
Carl June noted that the first genetic cause for leukemia was found in Philadelphia in 1960. Now, the University of Pennsylvania researcher hopes to make this the place where a cure is discovered for many leukemia patients. About 200 colleagues, friends, and patients touched by June's work gathered Friday evening at Penn's Perelman Center for Advanced Medicine to honor him as the 2012 recipient of the Philadelphia Award. Read More